Interaction between paliperidone extended release and TS-1&reg;, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient | Zendy

Norio YasuiFurukori | Zendy; Kazutoshi Kubo | Zendy; Kojiro Hashimoto | Zendy; Tetsu Tomita | Zendy

Open Access

Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient

Author(s) -

Norio YasuiFurukori,

Kazutoshi Kubo,

Kojiro Hashimoto,

Tetsu Tomita

Publication year - 2013

Publication title -

neuropsychiatric disease and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.819

H-Index - 67

eISSN - 1178-2021

pISSN - 1176-6328

DOI - 10.2147/ndt.s41738

Subject(s) - medicine , paliperidone , fluorouracil , derivative (finance) , pharmacology , anticancer drug , drug , schizophrenia (object oriented programming) , cancer , psychiatry , antipsychotic , financial economics , economics

Until now there has been no information available on drug interaction between paliperidone and TS-1(®), an oral anticancer drug containing a 5-fluorouracil derivative. The patient in the case presented here was a 39-year-old man with a 15-year history of schizophrenia. The patient's usual treatment of 2 mg/day of risperidone was changed to 3 mg/day of paliperidone extended release. He experienced worsening psychotic symptoms after switching from risperidone to paliperidone while he was also receiving TS-1. Retrospective analyses showed plasma concentration of paliperidone was consistently lower during the treatment with TS-1 than without TS-1. This case suggests there is drug interaction between paliperidone extended-release tablets and TS-1.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research